$MNPR News

Monopar Therapeutics Publishes Phase 2 Study Demonstrating ALXN1840 Improves Copper Balance In Patients With Wilson Disease

Reported Sunday, Monopar Presents Phase 3 Data At AAN 2026 Showing ALXN1840 Delivers Greater Neurologic Benefit And Lower Worsening Rates Versus Standard Of Care In Wilson Disease

Reported Sunday, Monopar Presents Phase 3 Data At AAN 2026 Showing ALXN1840 Delivers Greater Neurologic Benefit And Lower Worsening Rates Versus Standard Of Care In Wilson Disease

Monopar Therapeutics Q4 EPS $(0.61) Misses $(0.54) Estimate

BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target

Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them.

BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target

Morgan Stanley Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $115

Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount?

Raymond James Downgrades Monopar Therapeutics to Outperform, Lowers Price Target to $123

Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $100 Price Target

Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate

Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $100

Leerink Partners Initiates Coverage On Monopar Therapeutics with Outperform Rating, Announces Price Target of $115

Reported Sunday, Monopar Presents Phase 2 Data Showing Rapid Copper Balance Improvement In Wilson Disease Patients On Tiomolybdate Choline At AASLD 2025

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect?

Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025